High expression of proenkephalin is associated with favorable outcomes in patients with gastrointestinal stromal tumors

References

• Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumor. Lancet. 2007;369(9574):1731–1741. doi:10.1016/S0140-6736(07)60780-617512858
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–4349. doi:10.1200/JCO.2003.04.19014645423
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–710. doi:10.1126/science.107966612522257
   PubMed Web of Science ®Google Scholar
• Joensuu H, Rutkowski P, Nishida T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015;33(6):634–642. doi:10.1200/JCO.2014.57.497025605837
   PubMed Web of Science ®Google Scholar
• Gasparotto D, Rossi S, Polano M, et al. Quadruple-negative GIST is a sentinel for unrecognized neurofibromatosis type 1 syndrome. Clin Cancer Res. 2017;23(1):273–282. doi:10.1158/1078-0432.CCR-16-015227390349
   PubMed Web of Science ®Google Scholar
• Rossi S, Sbaraglia M, Dell’Orto MC, et al. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget. 2016;7(21):30109–30118. doi:10.18632/oncotarget.876827097112
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol. 2008;26(11):5360–5367. doi:10.1200/JCO.2007.15.277718955451
   PubMedGoogle Scholar
• Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160(5):1567–1572. doi:10.1016/S0002-9440(10)61103-012000708
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumors: origin and molecular oncology. Nat Rev Cancer. 2011;11(19):865–878. doi:10.1038/nrc314322089421
   PubMedGoogle Scholar
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–625. doi:10.1200/JCO.2007.15.277718235121
   PubMed Web of Science ®Google Scholar
• Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French sarcoma group. J Clin Oncol. 2007;25(9):1107–1113. doi:10.1200/JCO.2006.09.018317369574
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764–4774. doi:10.1200/JCO.2006.06.226516954519
   PubMed Web of Science ®Google Scholar
• Okada N, Kubota A, Imamura T, et al. Evaluation of cholecystokinin, gastrin, CCK-A receptor, and CCK-B/gastrin receptor gene expressions in gastric cancer. Cancer Lett. 1996;106(2):257–262. doi:10.1016/0304-3835(96)04325-X8844981
   PubMed Web of Science ®Google Scholar
• Phillips CM, Zatarain JR, Nicholls ME, et al. Upregulation of cystathionine-β-synthase in colonic epithelia reprograms metabolism and promotes carcinogenesis. Cancer Res. 2017;77(21):5741–5754. doi:10.1158/0008-5472.CAN-16-348028923859
   PubMed Web of Science ®Google Scholar
• Renz BW, Takahashi R, Tanaka T, et al. β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell. 2018;33(1):75–90. doi:10.1016/j.ccell.2017.11.00729249692
   PubMed Web of Science ®Google Scholar
• Padickakudy R, Pereyra D, Offensperger F, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol. 2017;67(6):1243–1252. doi:10.1016/j.jhep.2017.08.00928842294
   PubMed Web of Science ®Google Scholar
• Roperch JP, Incitti R, Forbin S, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566. doi:10.1186/1471-2407-13-56624289328
   PubMed Web of Science ®Google Scholar
• Foy JP, Pickering CR, Papadimitrakopoulou VA, et al. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015;8(11):1027–1035. doi:10.1158/1940-6207.CAPR-14-017926342026
   PubMed Web of Science ®Google Scholar
• Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood). 2013;238(5):579–587. doi:10.1177/153537021348848323856908
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head Neck. 2012;34(4):513–519. doi:10.1002/hed.2175921584896
   PubMed Web of Science ®Google Scholar
• Zagon IS, Porterfield NK, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Exp Biol Med (Maywood). 2013;238(6):589–599. doi:10.1177/153537021348949223918871
   PubMed Web of Science ®Google Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–1419. doi:10.1016/j.humpath.2008.06.02518774375
   PubMed Web of Science ®Google Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(5):536–563. doi:10.6004/jnccn.2018.002529752328
   PubMedGoogle Scholar
• Ma MZ, Zhuang C, Yang X, et al. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia. 2014;16(3):265–278. doi:10.1016/j.neo.2014.03.00124726140
   PubMed Web of Science ®Google Scholar
• Zagon IS, Wu Y, McLaughlin PJ. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol. 1996;106(3):490–497. doi:10.1111/1523-1747.ep123437128648182
   PubMed Web of Science ®Google Scholar
• Nissen JB, Kragballe K. Enkephalins modulate differentiation of normal human keratinocytes in vitro. Exp Dermatol. 1997;6(5):222–229. doi:10.1111/exd.1997.6.issue-59450624
   PubMed Web of Science ®Google Scholar
• Le Merrer J, Becker JA, Befort K, et al. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89(4):1379–1412. doi:10.1152/physrev.00005.200919789384
   PubMed Web of Science ®Google Scholar
• Kuis W, Villiger PM, Leser HG, Lotz M. Differential processing of proenkephalin-A by human peripheral blood monocytes and T lymphocytes. J Clin Invest. 1991;88(3):817–824. doi:10.1172/JCI1153821885771
   PubMed Web of Science ®Google Scholar
• Rosen H, Krichevsky A, Polakiewicz RD, et al. Developmental regulation of proenkephalin gene expression in osteoblasts. Mol Endocrinol. 1995;9(11):1621–1631. doi:10.1210/mend.9.6.85925118584038
   PubMedGoogle Scholar
• Behar O, Ovadia H, Polakiewicz RD, et al. Lipopolysaccharide induces proenkephalin gene expression in rat lymph nodes and adrenal glands. Endocrinology. 1994;134(1):475–478. doi:10.1210/endo.134.6.81944728275961
   PubMed Web of Science ®Google Scholar
• Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol. 1999;14(15):577–584.10024694
   PubMedGoogle Scholar
• Suzuki M, Chiwaki F, Sawada Y, et al. Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo. PLoS One. 2015;10(4):12–22. doi:10.1371/journal.pone.0123407
   Web of Science ®Google Scholar
• Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer. 2008;7(8):5–16. doi:10.1186/1476-4598-7-518190706
   PubMedGoogle Scholar
• McLaughlin PJ, Stack BC, Braine KM, et al. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol. 2004;24(1):227–232.14654962
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Jaglowski JR, Verderame MF, et al. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol. 2005;26(3):809–816.15703840
   PubMed Web of Science ®Google Scholar
• Zagon IS, Wu Y, McLaughlin PJ. Opioid growth factor inhibits DNA synthesis in mouse tongue epithelium in a circadian rhythm-dependent manner. Am J Physiol. 1994;267(3 Pt 2):R645–52.8092307
   PubMedGoogle Scholar
• Zagon IS, Roesener CD, Verderame MF, et al. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol. 2000;17(5):1053–1061.11029512
   PubMed Web of Science ®Google Scholar
• Jaglowski JR, Zagon IS, Stack BC, et al. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005;56(1):97–104. doi:10.1007/s00280-005-1000-915791460
   PubMed Web of Science ®Google Scholar